Collegium Pharmaceutical (NASDAQ:COLL) Hits New 52-Week Low – Here’s Why

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $23.11 and last traded at $23.37, with a volume of 1114849 shares traded. The stock had previously closed at $23.53.

Wall Street Analyst Weigh In

A number of brokerages recently commented on COLL. Zacks Research downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Truist Financial upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. Barclays lowered their price target on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating on the stock in a report on Wednesday, August 19th. Piper Sandler reaffirmed a “neutral” rating and set a $43.00 price target (down from $45.00) on shares of Collegium Pharmaceutical in a research note on Friday, August 7th. Finally, Weiss Ratings lowered Collegium Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Collegium Pharmaceutical presently has an average rating of “Moderate Buy” and an average target price of $51.00.

Collegium Pharmaceutical Stock Performance

The firm has a market cap of $760.93 million, a price-to-earnings ratio of 18.85 and a beta of 0.72. The firm’s 50 day moving average is $31.35 and its 200-day moving average is $33.90. The company has a debt-to-equity ratio of 3.32, a quick ratio of 0.84 and a current ratio of 1.03.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The company had revenue of $199.88 million during the quarter, compared to analysts’ expectations of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The business’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.68 earnings per share. Sell-side analysts anticipate that Collegium Pharmaceutical, Inc. will post 6.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Freestone Grove Partners LP acquired a new stake in shares of Collegium Pharmaceutical in the second quarter worth $1,611,000. Vanguard Group Inc. grew its stake in Collegium Pharmaceutical by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock valued at $104,465,000 after buying an additional 29,876 shares during the last quarter. Globeflex Capital L P bought a new position in Collegium Pharmaceutical in the 2nd quarter worth $1,915,000. Empowered Funds LLC bought a new position in Collegium Pharmaceutical in the 2nd quarter worth $2,045,000. Finally, Louisiana State Employees Retirement System acquired a new position in Collegium Pharmaceutical during the 1st quarter worth $463,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.